About Us - RAPT Therapeutics RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases
Homepage - RAPT Therapeutics RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and
Clinical and molecular effects of oral CCR4 . . . - RAPT Therapeutics RAPT Therapeutics will provide access to individual de-identified participant data from RAPT-sponsored interventional clinical stud-ies after a medicine has received regulatory approval in the United States or European Union, or after a program has been terminated
PowerPoint Presentation Corresponding author email address: bill ho@rapt com This study was sponsored by RAPT Therapeutics, Inc
Press Releases - RAPT Therapeutics RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 21 | 2025
Transforming the Treatment of Cancer and Inflammation - RAPT Therapeutics The Sponsor would like to thank Innovaderm Research Inc , members of the Guttman laboratory, contributors to the program at RAPT Therapeutics, Inc , study investigators, site staff, and the study participants for their support of and contributions to the trial
Template for Electronic Submission to ACS Journals - RAPT Therapeutics Oezcan Talay, James R Walker∆, Angela Wadsworth, David J Wustrow*, Mikhail Zibinsky* RAPT Therapeutics, 561 Eccles Avenue, South San Francisco, CA 94080 ABSTRACT Recruitment of suppressive CD4+ FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the anti-tumor response in patients
Pipeline - RAPT Therapeutics RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we are developing novel molecules that are designed to modulate the critical immune responses underlying these diseases